Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease, PMID: 24450891
Bapineuzumab, PMID: 20497044
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis, PMID: 22305802
Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?, PMID: 23574434
Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease, PMID: 21091109
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer Disease, PMID: 29920980
Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials, PMID: 28376794
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies, PMID: 32989305
Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study, PMID: 30129411
Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies, PMID: 27334799
Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials, PMID: 27176461
Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab, PMID: 21592055
Passive antiamyloid immunotherapy for Alzheimer's disease, PMID: 32040044
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease, PMID: 26639957
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β, PMID: 29686315
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab, PMID: 29429971
Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study, PMID: 29914022
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials, PMID: 33321511
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab, PMID: 27163805
Efficacy and safety of anti-amyloid- β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis, PMID: 29296624
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation, PMID: 23416764
Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies, PMID: 30412493
Bapineuzumab in Alzheimer's disease: where now?, PMID: 20129159
Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer's disease, PMID: 26044070
Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy, PMID: 23555764
Bapineuzumab, an investigational agent for Alzheimer's disease, PMID: 23599675
Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient, PMID: 21263194
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease, PMID: 27589523
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials, PMID: 29854934
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study, PMID: 20189881
A single ascending dose study of bapineuzumab in patients with Alzheimer disease, PMID: 20505438
APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics, PMID: 19923549
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis, PMID: 33046560
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials, PMID: 26208959
Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis, PMID: 25669746
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease, PMID: 22473769
Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease, PMID: 25187399
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab, PMID: 29854935
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716688
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24724181
Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients, PMID: 28269765
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease, PMID: 19923550
Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models, PMID: 26467270
[Immunotherapy for Alzheimer's disease], PMID: 26815584
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716689
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716687
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies, PMID: 22339463
Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β, PMID: 24598931
Disease modifying drugs targeting β-amyloid, PMID: 22815077
Tau aggregates as immunotherapeutic targets, PMID: 23277060
Characterizing Treatment Non-responders and Responders in Completed Alzheimer's Disease Clinical Trials., PMID:40417467
A non-parametric U-statistic testing approach for multi-arm clinical trials with multivariate longitudinal data., PMID:40416930
The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer's Dementia: A Systematic Review., PMID:40346804
Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives., PMID:39865265
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer's disease., PMID:39434125
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease., PMID:39432414
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders., PMID:38928395
A Review of Recent Advances in the Management of Alzheimer's Disease., PMID:38756263
Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities., PMID:38740836
Passive immunotherapy for Alzheimer's disease: challenges & future directions., PMID:38715084
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease., PMID:38685682
Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody., PMID:38634473
Correction: Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncted Abeta in sporadic Alzheimer disease cases and mouse models., PMID:38526686
Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications., PMID:38312931
Characterizing Treatment Non-responders vs. Responders in Completed Alzheimer's Disease Clinical Trials., PMID:37961216
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer's disease in 2023., PMID:37749530
Monoclonal Antibody Treatments for Alzheimer's Disease: Aducanumab and Lecanemab., PMID:39726673
Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis., PMID:37423541
Safety Analysis of Bapineuzumab in the Treatment of Mild to Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis., PMID:37076966
Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease., PMID:37006475
Learnings about Aβ from human brain recommend the use of a live-neuron bioassay for the discovery of next generation Alzheimer's disease immunotherapeutics., PMID:36899414
A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease., PMID:36632701
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer's disease with a bispecific, brain-penetrating fusion protein., PMID:36567338
Therapeutic anti-amyloid β antibodies cause neuronal disturbances., PMID:36515320
Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model)., PMID:36454709
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease., PMID:35557606
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy., PMID:35542992
Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab., PMID:35493943
Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease., PMID:35100444
Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease., PMID:33938131
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease., PMID:33831607
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials., PMID:33321511
Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology., PMID:33189132
Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease., PMID:33050199
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis., PMID:33046560
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies., PMID:32989305
Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle., PMID:32779267
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease., PMID:32682954
N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer's disease., PMID:32497293
Progression of Alzheimer's disease and effect of scFv-h3D6 immunotherapy in the 3xTg-AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy., PMID:32067292
Passive antiamyloid immunotherapy for Alzheimer's disease., PMID:32040044
Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review., PMID:31325011
Treatment with scFv-h3D6 Prevented Neuronal Loss and Improved Spatial Memory in Young 3xTg-AD Mice by Reducing the Intracellular Amyloid-β Burden., PMID:31306135
Pharmacokinetic parameters and mechanism of action of an efficient anti-Aβ single chain antibody fragment., PMID:31150495
Thousands of amyloids may foil Alzheimer's drugs., PMID:30718876
SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)., PMID:30486882
Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies., PMID:30412493
Detection of amyloid β oligomers toward early diagnosis of Alzheimer's disease., PMID:30267709
Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy., PMID:30201212
Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study., PMID:30129411
For research use only. Not for human or drug use.
